215 related articles for article (PubMed ID: 17283171)
1. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma.
Du Y; Honeychurch J; Glennie M; Johnson P; Illidge T
Cancer Res; 2007 Feb; 67(3):1335-43. PubMed ID: 17283171
[TBL] [Abstract][Full Text] [Related]
2. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
3. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
4. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
8. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
9. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy.
Du Y; Honeychurch J; Cragg MS; Bayne M; Glennie MJ; Johnson PW; Illidge TM
Blood; 2004 Feb; 103(4):1485-94. PubMed ID: 14576070
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
Tutt AL; French RR; Illidge TM; Honeychurch J; McBride HM; Penfold CA; Fearon DT; Parkhouse RM; Klaus GG; Glennie MJ
J Immunol; 1998 Sep; 161(6):3176-85. PubMed ID: 9743386
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
Illidge T; Honeychurch J; Vandersteen A; Cragg M
Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
[TBL] [Abstract][Full Text] [Related]
12. Single-cell cytotoxicity with radiolabeled antibodies.
Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
[TBL] [Abstract][Full Text] [Related]
13. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
Michel RB; Brechbiel MW; Mattes MJ
J Nucl Med; 2003 Apr; 44(4):632-40. PubMed ID: 12679410
[TBL] [Abstract][Full Text] [Related]
14. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas.
Peterson JA; Blank EW; Ceriani RL
Cancer Res; 1997 Mar; 57(6):1103-8. PubMed ID: 9067279
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of malignancies.
Reilly RM
Clin Pharm; 1991 May; 10(5):359-75. PubMed ID: 2049898
[TBL] [Abstract][Full Text] [Related]
18. Determinants of the antitumor effect of radiolabeled monoclonal antibodies.
Knox SJ; Levy R; Miller RA; Uhland W; Schiele J; Ruehl W; Finston R; Day-Lollini P; Goris ML
Cancer Res; 1990 Aug; 50(16):4935-40. PubMed ID: 2379158
[TBL] [Abstract][Full Text] [Related]
19. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma.
Bridges SH; Kruisbeek AM; Longo DL
J Immunol; 1987 Dec; 139(12):4242-9. PubMed ID: 3500981
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy for B-cell lymphomas.
Green DJ; Pagel JM; Pantelias A; Hedin N; Lin Y; Wilbur DS; Gopal A; Hamlin DK; Press OW
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5598s-5603s. PubMed ID: 17875795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
